Achieve Life(ACHV) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
Yahoo FinanceMar 20 18:25 ET
Insider Purchase: Chief Financial Officer of $ACHV Buys 10,000 Shares
Quiver QuantitativeMar 19 16:47 ET
Achieve Life Sciences: Promising Clinical Progress and Strategic Leadership Enhancements Justify Buy Rating
TipRanksMar 12 13:05 ET · Ratings
Lake Street Maintains Achieve Life(ACHV.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsMar 12 06:31 ET · Ratings
JonesTrading Maintains Achieve Life(ACHV.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsMar 12 06:31 ET · Ratings
Analysts Are Bullish on Top Healthcare Stocks: Achieve Life Sciences (ACHV), Dexcom (DXCM)
TipRanksMar 11 15:50 ET · Ratings

Comments

Teddy123

Feb 10 21:46

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

$Achieve Life (ACHV.US)$
Achieve's Smoking Cessation Drug Hits Critical FDA Safety Milestone in Phase 3 Trial

Jaguar8

Feb 10 21:30

NEWS

$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
Monday, 10th February at 8:30 am
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial
Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025
SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company...

2

Jaguar8

Jan 7 21:35

NEWS

$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Tuesday, 7th January at 8:30 am
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified
Planned Cytisinicline NDA Submission on...

MindOverMatter

Aug 14, 2024 08:03

$Achieve Life (ACHV.US)$

3

2

Jaguar8

May 29, 2024 20:01

NEWS

$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...

ACHV Achieve Life

Trade Overview

Capital Trend

News

Comments

Market Insights